Stephens Investment Management Group LLC Has $18.80 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

Stephens Investment Management Group LLC grew its position in Insulet Co. (NASDAQ:PODD) by 10.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 80,792 shares of the medical instruments supplier’s stock after purchasing an additional 7,726 shares during the quarter. Stephens Investment Management Group LLC’s holdings in Insulet were worth $18,804,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of PODD. US Bancorp DE raised its holdings in shares of Insulet by 1.6% during the third quarter. US Bancorp DE now owns 14,347 shares of the medical instruments supplier’s stock worth $3,339,000 after acquiring an additional 227 shares during the period. Congress Asset Management Co. raised its holdings in shares of Insulet by 15.8% during the third quarter. Congress Asset Management Co. now owns 55,900 shares of the medical instruments supplier’s stock worth $13,011,000 after acquiring an additional 7,629 shares during the period. Diversify Wealth Management LLC raised its holdings in shares of Insulet by 18.1% during the third quarter. Diversify Wealth Management LLC now owns 1,827 shares of the medical instruments supplier’s stock worth $429,000 after acquiring an additional 280 shares during the period. New York State Teachers Retirement System raised its holdings in shares of Insulet by 0.9% during the third quarter. New York State Teachers Retirement System now owns 64,073 shares of the medical instruments supplier’s stock worth $14,913,000 after acquiring an additional 595 shares during the period. Finally, Diversify Advisory Services LLC acquired a new stake in shares of Insulet during the third quarter worth $217,000.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. BTIG Research raised their price objective on shares of Insulet from $250.00 to $260.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Barclays raised their price objective on shares of Insulet from $200.00 to $220.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. UBS Group raised their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Piper Sandler raised their target price on shares of Insulet from $230.00 to $285.00 and gave the company an “overweight” rating in a research report on Tuesday, September 17th. Finally, Canaccord Genuity Group raised their target price on shares of Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $242.29.

Insulet Stock Performance

Shares of PODD opened at $235.61 on Friday. The firm has a 50-day moving average of $227.10 and a 200-day moving average of $201.20. Insulet Co. has a one year low of $137.68 and a one year high of $243.98. The company has a market cap of $16.52 billion, a PE ratio of 42.84, a price-to-earnings-growth ratio of 4.30 and a beta of 1.21. The company has a debt-to-equity ratio of 1.36, a current ratio of 3.60 and a quick ratio of 2.71.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported $0.55 EPS for the quarter, missing analysts’ consensus estimates of $0.56 by ($0.01). Insulet had a net margin of 21.11% and a return on equity of 30.73%. The firm had revenue of $488.50 million during the quarter, compared to the consensus estimate of $488.00 million. During the same period last year, the business earned $0.38 EPS. The business’s revenue was up 23.2% on a year-over-year basis. As a group, equities analysts forecast that Insulet Co. will post 3.04 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.